ADAR1: from basic mechanisms to inhibitors

Journal article : Review

Adenosine deaminase acting on RNA 1 (ADAR1) converts adenosine to inosine in double-stranded RNA (dsRNA) molecules, a process known as A-to-I editing. ADAR1 deficiency in humans and mice results in profound inflammatory diseases characterised by the spontaneous induction of innate immunity. In cells lacking ADAR1, unedited RNAs activate RNA sensors. These include melanoma differentiation-associated gene 5 (MDA5) that induces the expression of cytokines, particularly type I interferons (IFNs), protein kinase R (PKR), oligoadenylate synthase (OAS), and Z-DNA/RNA binding protein 1 (ZBP1). Immunogenic RNAs 'defused' by ADAR1 may include transcripts from repetitive elements and other long duplex RNAs. Here, we review these recent fundamental discoveries and discuss implications for human diseases. Some tumours depend on ADAR1 to escape immune surveillance, opening the possibility of unleashing anticancer therapies with ADAR1 inhibitors.

Authors: Rehwinkel, J; Mehdipour, P

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Cell Press
• Journal: Trends in Cell Biology
• Volume: 35
• Issue: 1
• Pages: 59-73
• Place of publication: England
• Publication date: 2024-07-18
• Acceptance date: 2024-06-20
• DOI: 10.1016/j.tcb.2024.06.006
• EISSN: 1879-3088
• ISSN: 0962-8924
• Pmid: 39030076
• Language: English
• Keywords: innate immunity; MDA5; RNA editing; ZBP1; type I interferon; ADAR1
• Subtype: Review